Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Net Cash Flow (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Net Cash Flow for 17 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 96.82% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$29.3 million through Dec 2025, down 24.53% year-over-year, with the annual reading at -$29.3 million for FY2025, 24.53% down from the prior year.
  • Net Cash Flow hit $1.3 million in Q4 2025 for Integra Lifesciences Holdings, down from $15.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $320.5 million in Q1 2024 to a low of -$375.5 million in Q2 2024.
  • Historically, Net Cash Flow has averaged -$11.5 million across 5 years, with a median of -$6.6 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 832.74% in 2024; the steepest drop was 18527.13% in 2024.
  • Year by year, Net Cash Flow stood at $42.3 million in 2021, then tumbled by 258.78% to -$67.2 million in 2022, then skyrocketed by 92.01% to -$5.4 million in 2023, then skyrocketed by 832.74% to $39.3 million in 2024, then crashed by 96.82% to $1.3 million in 2025.
  • Business Quant data shows Net Cash Flow for IART at $1.3 million in Q4 2025, $15.1 million in Q3 2025, and -$33.9 million in Q2 2025.